

The Börjeson–Forssman–Lehman syndrome (BFLS, MIM #301900)

Börjeson–Forssman–Lehman syndrome was first described in 1962. Many similar families and isolated cases have been reported since. In nineteen of them, including the original family, the clinical diagnosis was confirmed by the identification of a mutation in the responsible gene, *PHF6*. Summarizing recent clinical and molecular studies of this X-chromosome linked mental retardation syndrome we aim to offer a useful resource for its identification among the affected male and female subjects.

In brief

- BFLS is an uncommon, syndromic form of X-linked mental retardation.
- Males are predominantly affected but milder manifestations may be seen in females.
- Pregnancy and birth weight are normal but feeding problems and hypotonia are common in infancy.
- Developmental delay is evident early; later intellectual handicap is mild to moderate.
- Major physical features are large, fleshy earlobes, foreshortened toes and small genitalia.
- Gynaecomastia, truncal obesity, tapered fingers and some coarsening of facial features emerge through childhood and adolescence.
- Mutations in the zinc finger gene *PHF6* are the cause of BFLS.
- There is no evidence for genetic heterogeneity of BFLS.
- Function of the *PHF6* protein and molecular pathogenesis of BFLS is not known.
- Management is symptomatic. Genetic counseling is indicated.

Clinical overview

Börjeson–Forssman–Lehman syndrome (BFLS) is a relatively uncommon type of syndromic X-linked mental retardation that has now been well described in 19 families and isolated cases with mutations in the responsible gene, *PHF6*.^{1–3} It is

clear that the main clinical features evolve with age and show considerable variation both within and between families.^{4,5}

Pregnancy, delivery and birth weight are normal. Small genitalia and large ears may be evident at birth and many infants have generalized hypotonia and poor feeding. Developmental delay is usually evident before the first birthday; the eventual degree of mental handicap is mild to moderate. The head circumference is usually normal but macrocephaly and microcephaly occur. The ears are large with fleshy lobes. Moderate short stature is the rule but may be marked and, by contrast, some reach normal height. Truncal obesity emerges in late childhood and gynaecomastia in adolescence (see Figure 1). The genitalia remain small. The fingers are tapered and malleable. The feet are broad with foreshortened, often flexed, toes (see Figure 1). In adult life there is some coarsening of the facial features with prominence of the supraorbital ridges and deep-set eyes (Figure 1, panels a and b). Less common findings have been a mild generalized polyneuropathy,⁵ epilepsy, Perthes disease, hearing impairment, cleft lip and palate and hypopituitarism. Female heterozygotes may have learning problems and show some physical manifestations particularly shortened toes, thickened, fleshy ear

Jozef Gécz^{*1,2}, Gillian Turner³, John Nelson⁴ and Michael Partington³

¹Department of Genetic Medicine, Women's and Children's Hospital, North Adelaide, South Australia, Australia; ²Department of Paediatrics, The University of Adelaide, Adelaide, South Australia, Australia; ³Hunter Genetics and University of Newcastle, New South Wales, Australia; ⁴Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, Western Australia, Australia

European Journal of Human Genetics (2006) 14, 1233–1237.
doi:10.1038/sj.ejhg.5201639

Keywords: X-linked mental retardation; *PHF6*; gynaecomastia; large ears; foreshortened toes; truncal obesity

*Correspondence: Dr J Gecz, Neurogenetics laboratory, Department of Genetic Medicine, Women's and Children's Hospital, North Adelaide, South Australia 5006, Australia.

Tel: +61 8 8161 6339; Fax: +61 8 8161 7342;

E-mail jozef.gecz@adelaide.edu.au

Received 6 January 2006; revised 7 March 2006; accepted 7 March 2006; published online 16 August 2006



Figure 1 Photographs of affected males with BFLS. Panels (a–d) show a BFLS patient with deep-set eyes, ptosis, prominent supraorbital ridges, large ears and earlobes, fleshy tapered fingers, a short fourth metatarsal with short flexed toes and a broad toe (from family F18, see Table 1). Panels (e–g) show three adolescent patients with gynaecomastia at the age of 12 years (from family F6, see Table 1) and two brothers 14- and 13-year-old (from family F16, see Table 1). Panels (e–g) were reproduced with kind permission from Blackwell Publishing Ltd from *Clin Genet* 2004 March; **65**(3): 226–232.

lobes, pronounced supraorbital ridges and deep-set eyes. The pattern of inheritance is X linked.

Differential diagnosis

Many mentally retarded boys are obese but few have BFLS. The most helpful clinical diagnostic features are the long, fleshy earlobes; shortened, abnormal toes; tapered, malleable fingers, gynaecomastia and moderate obesity in adolescence and underdeveloped, external genitalia. This

cluster of signs occurs in 90% or more of those boys where mutations in *PHF6* are found. Other useful diagnostic features are moderate hypotonia and feeding difficulties in infancy, and, in adults, some coarsening of the facial appearance with deep-set eyes and prominent supraorbital ridges. In the early descriptions of this syndrome microcephaly and short stature were emphasized but although these do occur they are not common.

With a clear X linked pedigree the main differential diagnosis is the Coffin–Lowry syndrome (CLS; MIM #303600). However, in CLS, the characteristic facies

appears early in life with hypertelorism, downslanting eyes, short nose and thick everted lips; the ears are not enlarged; height is less than the third centile; kyphoscoliosis and pectus excavatum and carinatum are common; mental retardation is more severe and occurs more often in heterozygotes; mutations in *RSK2* can be demonstrated. Other, less well-defined, single families with X linked mental retardation and obesity have been described; in only one of these has the gene been mapped (Wilson–Turner syndrome; Xp21.1–q22; MIM #309585).

In the isolated male with BFLS, Klinefelter syndrome may be suggested but this syndrome lacks the tapered fingers and short toes and has an abnormal karyotype. The Prader–Willi syndrome (MIM #176270) has some resemblances but neonatal hypotonia and feeding problems are more severe, subsequent hyperphagia is distinctive, obesity is more extreme and the characteristic fingers and toes are lacking. Isolated heterozygote females might be mistaken for CLS or pseudohypoparathyroidism.

Gene

The *PHF6* gene was identified in 2002 by Lower *et al.*¹ It is a member of a large family of zinc-finger genes. *PHF6* is transcribed as a ~4.5 kb mRNA, which shows a ubiquitous expression pattern as tested by Northern blot hybridization¹ and RT PCR.⁶ Two major isoforms exist. These differ in the inclusion or exclusion of intron 10 from the mRNA. Although this alternative splicing does not change the *PHF6* protein it might be involved in the regulation of *PHF6* mRNA stability and/or translation. However, this is only speculation, which needs further experimental

substantiation.¹ More recently, Landais *et al.*⁶ reported the existence of six other isoforms of the *Phf6* gene in mouse. Their function is not clear although five of them (t1, t4, t5, t6 and t7) can potentially give rise to alternative *Phf6* protein isoforms. These new *Phf6* mRNA isoforms are infrequent (<2%) and identified only by analysis of ESTs without further validation.

The *PHF6* gene is highly conserved in vertebrates, but has no obvious ortholog(s) in lower organisms (ie, insects or yeast).¹ Its ubiquitous expression pattern together with high conservation, and in particular, within the plant homeodomain (PHD) finger domains, suggests an important cellular role.

PHF6 mutations and mutation screening

There are 19 unrelated cases of BFL syndrome with confirmed *PHF6* gene mutations reported in the literature.^{1–3,5,7,8} Among these are 13 patients with a positive family history, including the original family described by M Börjeson, H Forssman and O Lehmann in 1962,¹⁰ and six isolated cases. These mutations are summarized in Table 1. Overall there are 12 different mutations found, predominantly missense and truncation mutations. Five of these mutations are recurrent, with the c.1024C>T/p.R342X truncating mutation being the most frequent, found in 4 out of 19 cases (21%). The *PHF6* mutations do not seem to cluster although mutations in or around exon 2 and in exon 10 account for 13/19 (68.4%) mutations found so far. Where it was possible to investigate this,^{1,5} it was confirmed that identical mutations are not identical by descent and arose independently. Some of these mutations,

Table 1 Summary of the currently known mutations in the *PHF6* gene

Family	Fam. (F) Isol. (I)	Exon	Nucleotide position	Amino-acid change	Class of mutation	Ref.
1	F	Exon 2	2T>C	M1T	Missense	Lower <i>et al</i> ¹ (#6)
2	F	Exon 2	2T>C	M1T	Missense	Crawford <i>et al</i> ² (#2)
3	F	Exon 2	22A>T	K8X	Truncation	Lower <i>et al</i> ¹ (#9)
4	I*	Exon 2	27_28insA	G10fsX21	Truncation	Crawford <i>et al</i> ² (#3)
5	F	Exon 2	134G>A	C45Y	Missense	Lower <i>et al</i> ¹ (#4)
6	I	Exon 2	134G>A	C45Y	Missense	Lower <i>et al</i> ¹ (#8)
7	F	Intron 2	IVS2-8A>G	M46fs	Truncation	Vallee <i>et al</i> ⁵ (#2)
8	I	Exon 4	296G>T	C99F	Missense	Lower <i>et al</i> ¹ (#2)
9	F	Exon 7	686A>G	H229R	Missense	Lower <i>et al</i> ¹ (#5)
10	F	Exon 7	700A>G	K234E	Missense	Lower <i>et al</i> ¹ (#3)
11	F	Exon 8	769A>G	R257G	Missense	Lower <i>et al</i> ¹ (#7)
12	I	Exon 8	769A>G	R257G	Missense	Vallee <i>et al</i> ⁵ (#1)
13	I	Exon 9	940A>G	I314V	Missense	Crawford <i>et al</i> ² (#1)
14	F	Exon 10	999_1001delTGA	D333del	Deletion	Baumstark <i>et al</i> ⁷ (#1)
15	F	Exon 10	999_1001delTGA	D333del	Deletion	Börjeson <i>et al</i> ¹⁰ (#2)
16	F	Exon 10	1024C>T	R342X	Truncation	Lower <i>et al</i> ¹ (#1)
17	F	Exon 10	1024C>T	R342X	Truncation	Lower <i>et al</i> ² (#1)
18	F	Exon 10	1024C>T	R342X	Truncation	Lower <i>et al</i> ² (#3)
19	I	Exon 10	1024C>T	R342X	Truncation	Börjeson <i>et al</i> ¹⁰ (#1)

*Indicates the only female BFLS patient with *PHF6* mutation identified so far. Shading highlights identical mutations by site. These mutations are not identical by descent. The numbers in the parentheses after the references refer to particular families/isolated cases as described in that work.

like c.27_28insA/G10fsX21 (case 3 of Crawford *et al*²) or c.1024C>T/p.R342X (family 3 of Lower *et al*⁵) arose *de novo* (likely on the paternal chromosome as experimentally confirmed for case 3 of Crawford *et al*²).

Current² and past^{1,5} experience with mutation screening tells us that there are no known familial cases with clinically diagnosed BFL syndrome where mutations in the *PHF6* gene were not found. This, together with the identification of the *PHF6* mutation in the original BFLS family^{5,10} suggests that unlike many other XLMR syndromes¹¹ BFLS is not genetically heterogeneous. However, this does not mean that clinical and molecular diagnoses are well aligned as *PHF6* mutation pickup rate in clinically diagnosed individuals with BFLS (predominantly isolated cases, 20/25) is relatively low, 5/25 cases (20%).²

When considering screening for *PHF6* gene mutations in patients with suspected clinical diagnosis of BFLS it might be worthwhile to consider the family history (as for any other X-linked syndrome) and X-inactivation skewing in the patient (if female) or the mother of the patient (if male). One has to acknowledge that *de novo* mutations will go undetected if these criteria were applied strictly, but a positive family history and X-inactivation skewing would provide an additional incentive to screen for *PHF6* in patients where the clinical picture is not clear cut. Presently there is no evidence to suggest that mutations in *PHF6* cause other syndromic or nonsyndromic X-linked mental retardation or phenotypes other than BFLS.

X-inactivation skewing in carrier females

The status of X inactivation in obligate carrier females of *PHF6* mutations has recently been discussed.² It appears that although it is much more likely for a *PHF6* mutation carrier female to have skewed (>70%; three families) or highly skewed (>90%; seven families) X inactivation, there are also families (three families) where the X inactivation is random.² There is no obvious correlation between a particular *PHF6* mutation and X-inactivation skewing and X inactivation can vary among the members of the same family. Nor is there a clear cut correlation between the X-inactivation skewing (as measured almost invariably on white blood cells) and the variability of clinical presentation of the BFLS phenotype in carrier females. The only female patient diagnosed with BFLS and confirmed *PHF6* mutation (case #3 of Crawford *et al*) had highly skewed X inactivation in peripheral blood cells with an estimated 93% of the cells expressing the normal *PHF6* allele.² Similar levels of X-inactivation skewing were identified in several other BFLS carriers although their phenotype was mostly normal or very mild.^{2,4} These observations suggest that the level of X-inactivation skewing as measured in peripheral blood cells is currently not a reliable predictor of the penetrance of the BFLS

features in obligate carriers of *PHF6* mutations. Ascertainment of new cases will help to resolve this issue.

Function of the protein

PHF6 is a relatively small, unremarkable protein of 365 amino acids. It contains two similar PHD fingers.¹ Similar PHD fingers are found in proteins involved in regulation of transcription function (eg MLL, MLL2, MLL4, PHF11; J. Géczy, unpublished data), which was the function also proposed for PHD fingers.¹¹ Interestingly, there is only one *PHF6* mutation known, which directly affects critical residue of the first PHD finger, cytosine at position 99 (C99F).¹ In addition to the PHD fingers the *PHF6* protein also contains multiple (at least four clearly recognizable and functional)^{1,6} nuclear localization sequences. Subcellular localization studies show that the *PHF6* protein is localized in the cell nucleus and more prominently in the nucleolus.^{1,6,8} Traditionally, this organelle has been known as the ribosome assembly factory. However, as our knowledge advances it has been suggested that the nucleolus plays an important role, among others, in nuclear export, sequestering regulatory molecules, modifying small RNAs, cell cycle regulation and processes of aging.^{12,13} The role of the *PHF6* protein in the nucleolus is not known. More recently, mouse *Phf6* protein was found overexpressed in tumors with rearrangements (radiation leukemia virus, RadLV integration) in the neighboring *Kis2* locus (noncoding RNA; Unigene cluster Mm.277876, ~250 kb proximal to the *Phf6* gene).⁶ Overall there is very little information on the function of the *PHF6* protein available. If we dare to speculate, based on the X-inactivation skewing in carrier females,^{1,2} localization of the *PHF6* protein to the cell nucleus and nucleolus^{1,6,8} and the latest observations of the *Phf6* protein overexpression in specific mouse tumors,⁶ we would suggest an important role for *PHF6* in cell growth and proliferation, which may be achieved via its participation in ribosome biogenesis (at the RNA and/or protein level).

Management

There is no specific treatment. Special education is required from early life and adults require a variable degree of supervision. Sexual activity is minimal but strong social relationships can be formed. Symptomatic treatment may be needed for seizures, Perthes disease and hearing impairment. In individual patients, a case may be made for bilateral mastectomy and/or testosterone replacement therapy. The family requires genetic counseling for X linkage and the information that identification of female heterozygotes and prenatal diagnosis are now possible.

Electronic database information and accession numbers

MIM was accessed at <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM>; *PHF6* gene & protein information was accessed at Entrez Gene <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene>; BFLS, MIM no. 301900; *PHF6* gene, MIM no. 300414, GenBank nos. NM_001015877, NM_032335 and NM_032458.

Acknowledgements

This work was carried out with the support of the National Health and Medical Research Council of Australia.

References

- 1 Lower KM, Turner G, Kerr BA *et al*: Mutations in *PHF6* are associated with Börjeson–Forssman–Lehmann syndrome. *Nat Genet* 2002; **32**: 661–665.
- 2 Crawford J, Lower KM, Hennekam RC *et al*: Mutation screening in Börjeson–Forssman–Lehmann Syndrome (BFLS): identification of a novel, de novo *PHF6* mutation in a female patient. *J Med Genet* 2005; **July 25**: ; [E-pub ahead of print].
- 3 Just W, Mucke J: Towards a genotype-phenotype correlation in individuals with Börjeson–Forssman–Lehmann Syndrome. *ESHG Meeting Abstract P0631* 2005, Prague.
- 4 Turner G, Lower KM, White SM, *et al*: The clinical picture of the Börjeson–Forssman–Lehmann syndrome in males and heterozygous females with *PHF6* mutations. *Clin Genet* 2004; **65**: 226–232.
- 5 Lower KM, Solders G, Bondeson ML *et al*: 1024C>T (R342X) is a recurrent *PHF6* mutation also in the original Börjeson–Forssman–Lehmann syndrome family. *Eur J Hum Genet* 2004; **12**: 787–789.
- 6 Landais S, Quantin R, Rassart E: Radiation leukemia virus common integration at the *Kis2* locus: simultaneous overexpression of a novel noncoding RNA and of the proximal *Phf6* gene. *J Virol* 2005; **79**: 11443–11456.
- 7 Baumstark A, Lower KM, Sinkus A *et al*: Novel *PHF6* mutation p.D333del causes Börjeson–Forssman–Lehmann syndrome. *J Med Genet* 2003; **40**: e50.
- 8 Vallee D, Chevrier E, Graham GE *et al*: A novel *PHF6* mutation results in enhanced exon skipping and mild Börjeson–Forssman–Lehmann syndrome. *J Med Genet* 2004; **41**: 778–783.
- 9 Börjeson M, Forssman H, Lehmann O: An X-linked, recessively inherited syndrome characterized by grave mental deficiency, epilepsy, and endocrine disorder. *Acta Med Scand* 1962; **171**: 13–21.
- 10 Frints SG, Froyen G, Marynen P, Fryns JP: X-linked mental retardation: vanishing boundaries between non-specific (MRX) and syndromic (MRXS) forms. *Clin Genet* 2002; **62**: 423–432.
- 11 Aasland R, Gibson TJ, Stewart AF: The PHD finger: implication for chromatin-mediated transcriptional regulation. *Trends Biochem Sci* 1995; **20**: 56–59.
- 12 Olson MOJ, Dunder M, Szebeni A: The nucleolus: old factory with unexpected capabilities. *Cell Biol* 2000; **10**: 189–196.
- 13 Visitin R, Amon A: The nucleolus: the magician's hat for cell cycle tricks. *Curr Opin Cell Biol* 2000; **12**: 372–377.